Castration-resistant prostate cancer (mCRPC) presents a major challenge
for healthcare professionals. Despite recent advances, treatment options for
this deadly disease remain limited. CAR-T therapy, which involves modifying
immune cells to specifically target and destroy cancer cells, has shown
promise; however, its effectiveness against solid tumors has yet to be
confirmed.
This study explores the potential of CAR-T cells in treating mCRPC,
specifically targeting the Prostate Stem Cell Antigen (PSCA). The primary
objective is to assess the efficacy, safety, and potential effects of this
approach in addressing the unmet therapeutic needs of patients with mCRPC.
CAR-T PSCA Therapy: Results And Initial Clinical Observations
In this study, 14 patients with significant PSCA expression and advanced
mCRPC were divided into three cohorts, each receiving increasing doses of PSCA
CAR-T cells, with some patients undergoing prior lymphodepletion (LD):
- Cohort
DL1: 100 million CAR-T
cells without lymphodepletion.
- Cohort
DL2: 100 million CAR-T
cells with standard lymphodepletion.
- Cohort
DL3: 100 million CAR-T
cells with reduced lymphodepletion.
The primary endpoint was safety, specifically the occurrence of
dose-limiting toxicities (DLTs).
The results showed an antitumor response in 4 out of 14 patients, with a
30% reduction in prostate-specific antigen levels. Dynamic changes in the
composition of peripheral blood T cells confirmed immune system activation.
Radiographic improvements in some participants indicated a reduction in tumor
mass. Additionally, a moderate cytokine release syndrome was observed, without
severe neurological or immune toxicity. Overall, CAR-T therapy was well
tolerated, with grade 3 cystitis being the most common DLT.
Toward Optimizing CAR-T Therapies in mCRPC
These findings demonstrate that CAR-T cells
targeting the PSCA antigen represent a promising therapeutic approach for
mCRPC. Besides inducing an effective antitumor response, the safety profile is
acceptable. These results lay the groundwork for optimizing dosages and
combination strategies to enhance CAR-T cell persistence. Future directions for
this therapy could include adjustments in lymphodepletion, development of
next-generation CAR-T cells, and exploration of additional antigen targets to
maximize benefits for patients resistant to current treatments.
